YM BioSciences Inc. is a cancer drug development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator (for taxanes and anthracyclines) currently undergoing a pivotal Phase III trial in metastatic breast cancer. Tesmilifene has completed a previous Phase III trial with positive results. In addition to tesmilifene, the company is developing an EGFr humanized monoclonal antibody that has completed Phase II trials and a GnRH anti-cancer vaccine that is in earlier stage clinical trials.

"We are pleased to welcome YM BioSciences to the American Stock Exchange," said John McGonegal, senior vice president of the Amex Equities Group. "We look forward to working with an innovator such as YM BioSciences and providing them with the solid support and services that are essential in today's competitive marketplace."

"Listing on the Amex represents the achievement of another important milestone that we had set for 2004 in addition to the successful initiation of our 700 patient pivotal phase III clinical program for our lead anti-cancer drug, tesmilifene," said David Allan, Chairman and CEO of YM BioSciences. "In the past 10 months, our Company has raised more than US $30 million, the majority of these funds coming from U.S. life science investors. This listing will support our Company's growth, increasing our exposure to and facilitating further investment by U.S. investors."

The specialist for YM BioSciences Inc. will be Cohen Specialists, LLC. For further information on YMI and other Amex-listed companies, please visit www.amex.com.